Amicus Therapeutics, Inc. (NASDAQ:FOLD) Expected to Post Earnings of -$0.33 Per Share
Wall Street brokerages expect that Amicus Therapeutics, Inc. (NASDAQ:FOLD) will post earnings per share (EPS) of ($0.33) for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for Amicus Therapeutics’ earnings. The lowest EPS estimate is ($0.36) and the highest is ($0.31). Amicus Therapeutics reported earnings per share of ($0.31) during the same quarter last year, which would suggest a negative year-over-year growth rate of 6.5%. The company is expected to report its next quarterly earnings report on Monday, November 4th.
On average, analysts expect that Amicus Therapeutics will report full-year earnings of ($1.47) per share for the current financial year, with EPS estimates ranging from ($1.58) to ($1.06). For the next year, analysts expect that the firm will post earnings of ($1.03) per share, with EPS estimates ranging from ($1.33) to ($0.79). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that cover Amicus Therapeutics.
Amicus Therapeutics (NASDAQ:FOLD) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.34). The company had revenue of $44.13 million during the quarter, compared to analyst estimates of $41.14 million. Amicus Therapeutics had a negative return on equity of 66.79% and a negative net margin of 336.41%. Amicus Therapeutics’s quarterly revenue was up 107.1% on a year-over-year basis. During the same period in the prior year, the company posted ($0.33) earnings per share.
Shares of FOLD stock traded up $0.01 during trading on Wednesday, hitting $10.28. The company’s stock had a trading volume of 1,689,800 shares, compared to its average volume of 3,136,996. The company has a market cap of $2.62 billion, a PE ratio of -7.73 and a beta of 1.85. The company has a current ratio of 7.09, a quick ratio of 6.97 and a debt-to-equity ratio of 0.31. The business has a fifty day moving average of $11.85 and a 200-day moving average of $12.45. Amicus Therapeutics has a 52 week low of $8.27 and a 52 week high of $14.61.
In other Amicus Therapeutics news, Director Michael Raab sold 5,000 shares of the stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $11.16, for a total transaction of $55,800.00. Following the sale, the director now owns 13,895 shares in the company, valued at $155,068.20. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO John F. Crowley sold 20,000 shares of the stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $11.15, for a total value of $223,000.00. Following the sale, the chief executive officer now owns 770,399 shares in the company, valued at approximately $8,589,948.85. The disclosure for this sale can be found here. Over the last three months, insiders have sold 65,000 shares of company stock valued at $779,000. 2.50% of the stock is owned by corporate insiders.
Large investors have recently bought and sold shares of the business. Dimensional Fund Advisors LP lifted its stake in Amicus Therapeutics by 374.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,098,083 shares of the biopharmaceutical company’s stock worth $10,518,000 after purchasing an additional 866,793 shares in the last quarter. Marshall Wace LLP raised its position in Amicus Therapeutics by 6.9% in the 1st quarter. Marshall Wace LLP now owns 169,001 shares of the biopharmaceutical company’s stock valued at $2,299,000 after purchasing an additional 10,911 shares during the last quarter. DekaBank Deutsche Girozentrale raised its position in Amicus Therapeutics by 266.2% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 244,600 shares of the biopharmaceutical company’s stock valued at $2,935,000 after purchasing an additional 177,800 shares during the last quarter. Legal & General Group Plc raised its position in Amicus Therapeutics by 24.4% during the 4th quarter. Legal & General Group Plc now owns 82,835 shares of the biopharmaceutical company’s stock worth $793,000 after buying an additional 16,234 shares during the last quarter. Finally, Spark Investment Management LLC raised its position in Amicus Therapeutics by 105.0% during the 1st quarter. Spark Investment Management LLC now owns 1,606,400 shares of the biopharmaceutical company’s stock worth $21,847,000 after buying an additional 822,700 shares during the last quarter. Hedge funds and other institutional investors own 95.01% of the company’s stock.
About Amicus Therapeutics
Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.
See Also: Elliott Wave Theory
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.